The market supervision bureau of the Taizhou Medical High-tech Zone is working to transform intellectual property into capital value, providing financial support for local enterprises.

The NMPA recently approved the listing application of the lidocaine and prilocaine cream produced by Jiangsu Yingke Biopharmaceutical.

A technological breakthrough in the form of a SAW-DM32 fully automatic methylated nucleic acid extraction and purification instrument recently got the green light to be marketed.

The biggest integrated demonstration charging station, combining solar power generation, energy storage, charging and testing, recently started operating in Taizhou.

Overseas Pharmaceutical (Taizhou), located in China Medical City, strives to make its sustained-release preparations and controlled release preparations increasingly go global.

The Taizhou Medical City Biomedical Pilot Platform was included in the first group of national key cultivation pilot platforms.

Cellularforce, a leading one-stop service provider for Contract Development and Manufacturing Organization outsourcing manufacturing of antibody drugs in China, is on the move.

A new nutrition and intelligent health foods manufacturing base that is being operated by Jiangsu Beevip Biotechnology, started operating on April 7.